PharmiWeb

Global Minimally Invasive Surgery Market to Reach US$211.24 Billion by 2033, Says FutureWise Research

FutureWise Research, a leading provider of strategic market intelligence, has published an in-depth new market analysis ...
PharmiWeb

Novadip recruits first pediatric patients in pivotal phase 3 trial of tissue regenerative treatment NVD003 in congenital pseudoarthrosis of the tibia

Trial aims to enroll 12 children at eight sites in EU and USPhase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)Novadip aims to become ...
PharmiWeb

Sub-Saharan Africa Pharmaceuticals Market Industry Analysis , Opportunity Assessment And Forecast Till 2030: Medi-tech Insights

Sub-Saharan Africa Pharmaceuticals Market OutlookThe Sub-Saharan Africa (SSA) pharmaceuticals market is poised for strong expansion over the coming years, reflecting the region’s evolving healthcare ...
PharmiWeb

Atherectomy Devices Market to Witness a Leap by Leaching CAGR of 8% By The End Of 2029

Global Atherectomy Devices Market OverviewThe global atherectomy devices market is expected to witness substantial growth, with a projected CAGR of around 8% during the forecast period. Several key ...
PharmiWeb

Biovica Signs Client Bill Agreement with Leading U.S. NCI-Designated Cancer Center

UPPSALA, SE / ACCESS Newswire / December 15, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announced that the company ...
Opinion
PharmiWebOpinion

Budget speculation kills growth

Budget speculation kills growth Responding to the latest growth figures, Julian Jessop, Economics Fellow at the Institute of Economic Affairs said: "The further contraction in the UK economy in ...
PharmiWeb

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd , has entered into two strategic agreements with privately held Hasten ...
PharmiWeb

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official ...
PharmiWeb

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business ...
PharmiWeb

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ETBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and ...
PharmiWeb

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and …

FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against ...
PharmiWeb

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive B…

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...